NEW YORK--(BUSINESS WIRE)--Pluristem Life Systems, Inc. (OTCBB:PLRS), a cell therapy company dedicated to the commercialization of non personalized stem cell products for a variety of indications, today announced that the United States Food and Drug Administration’s (FDA) Center for Biological Evaluation and Research (CBER) accepted the Company’s proposed Pre-Investigation New Drug (PreIND) for its PLX-I product in pre-clinical studies for the treatment of hematological malignancies.
